Evidence map›Paper›PMID 29930163›Full record

Trial reportHaematologica2018

Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies.

Mara M Epstein, Bernard Rosner, Elizabeth C Breen, Julie L Batista, Edward L Giovannucci, Larry Magpantay, Jon C Aster, Scott J Rodig, Kimberly A Bertrand, Francine Laden and 2 more

Open access · goldAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Article
  6. AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  7. Immune Activation and Microbial Translocation as Prognostic Biomarkers for AIDS-Related Non-Hodgkin Lymphoma in the AMC-034 Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Mara M EpsteinDepartment of Medicine and the Meyers Primary Care Institute, University of Massachusetts Medical School, Worcester, MA, USA.
Bernard RosnerDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Elizabeth C BreenUCLA AIDS Institute, Los Angeles, CA, USA.
Julie L BatistaChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Edward L GiovannucciChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Larry MagpantayUCLA AIDS Institute, Los Angeles, CA, USA.
Jon C AsterDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Scott J RodigDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Kimberly A BertrandSlone Epidemiology Center at Boston University, Boston, MA, USA.
Francine LadenChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Otoniel Martínez-MazaUCLA AIDS Institute, Los Angeles, CA, USA.
Brenda M BirmannChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA brenda.birmann@channing.harvard.edu.
Harvard University · USBrigham and Women's Hospital · USBlack AIDS Institute · USBoston University · USUCLA Health · USUniversity of Massachusetts Chan Medical School · US

Funding

Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Cancer Epidemiology Cohort in Male Health ProfessionalsUM1CA167552 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2012 to 2016
$11.5M
University of Massachusetts Center for Clinical and Translational ScienceKL2TR001455 · NCATS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KIEFE, CATARINA I. · 2015 to 2024
$5.0M
A prospective analysis of peripheral blood cytokines and non-Hodgkin lymphomaR01CA149445 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BIRMANN, BRENDA M · 2011 to 2015
$3.0M
Exposure to Organochlorines, EBV, and the Risk of NHLR01CA098122 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI LADEN, FRANCINE · 2003 to 2006
$2.1M
NCI NIH HHS R01 CA098122NCI NIH HHS R01 CA149445NCI NIH HHS UM1 CA167552NCI NIH HHS UM1 CA186107
6 · The paper itself

Abstract

Inflammation and B-cell hyperactivation have been associated with non-Hodgkin lymphoma development. This prospective analysis aimed to further elucidate pre-diagnosis plasma immune marker profiles associated with non-Hodgkin lymphoma risk. We identified 598 incident lymphoma cases and 601 matched controls in Nurses' Health Study and Health Professionals Follow-up Study participants with archived pre-diagnosis plasma samples and measured 13 immune marker levels with multiplexed immunoassays. Using multivariable logistic regression we calculated Odds Ratios (OR) and 95% Confidence Intervals (CI) per standard deviation unit increase in biomarker concentration for risk of non-Hodgkin lymphoma and major histological subtype, stratifying additional models by years (<5, 5 to <10, ≥10) after blood draw. Soluble interleukin-2 receptor-α, CXC chemokine ligand 13, soluble CD30, and soluble tumor necrosis factor receptor-2 were individually positively associated, and B-cell activating factor of the tumor necrosis factor family inversely associated, with all non-Hodgkin lymphoma and one or more subtypes. The biomarker combinations associated independently with lymphoma varied somewhat by subtype and years after blood draw. Of note, the unexpected inverse association between B-cell activating factor and chronic lymphocytic leukemia/small lymphocytic lymphoma risk (OR: 95%CI: 0.51, 0.43-0.62) persisted more than ten years after blood draw (OR: 0.70; 95%CI: 0.52-0.93). In conclusion, immune activation precedes non-Hodgkin lymphoma diagnosis by several years. Decreased B-cell activating factor levels may denote nascent chronic lymphocytic leukemia many years pre-diagnosis.

Indexed as

Biomarkers, TumorLymphoma, Non-HodgkinNeoplasm ProteinsAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesBiomarkers, TumorNeoplasm Proteins

Identifiers

PMID29930163
PMCPMC6165815
OpenAlexW2809536934

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.